Literature DB >> 27170215

The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer.

Ying Wang1, Kwaku Appiah-Kubi1,2, Min Wu1, Xiaoyuan Yao3, Hai Qian1, Yan Wu1, Yongchang Chen1.   

Abstract

The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) play a key role in signaling pathways in oncogenesis. The overexpression of PDGFs and PDGFRs and the oncogenic alterations of these receptors have been implicated in human cancers and correlated significantly with poor outcomes. This review discusses the biology of the PDGF isoforms and receptors briefly, and their role in oncogenesis. Also, the attractiveness of targeting PDGFs and PDGFRs, based on a wide display of oncologic alterations in cancers, diverse therapeutic strategies, their roles in resistance to cancer treatments with prospects of overcoming drug resistance, and the extent to which validated biomarkers have been developed for effective PDGFs and PDGFRs-based cancer management are discussed.

Entities:  

Keywords:  PDGF isoforms; PDGF receptors; PDGFRs mutation; biomarker; cancer treatments; drug resistance

Mesh:

Substances:

Year:  2016        PMID: 27170215     DOI: 10.1080/08977194.2016.1180293

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  7 in total

1.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

Review 2.  Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy-Present State and Perspectives.

Authors:  Magdalena Olbryt
Journal:  Cancers (Basel)       Date:  2022-05-06       Impact factor: 6.575

3.  Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.

Authors:  Hiroki Yamazaki; Naoki Miura; Yu-Chang Lai; Masashi Takahashi; Yuko Goto-Koshino; Momoi Yasuyuki; Munekazu Nakaichi; Hajime Tsujimoto; Asuka Setoguchi; Yasuyuki Endo
Journal:  J Vet Med Sci       Date:  2017-06-06       Impact factor: 1.267

4.  Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression.

Authors:  Maria Tsioumpekou; Sara I Cunha; Haisha Ma; Aive Åhgren; Jessica Cedervall; Anna-Karin Olsson; Carl-Henrik Heldin; Johan Lennartsson
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 5.  PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy.

Authors:  Jie Xu; Lu Xie; Wei Guo
Journal:  Clin Sarcoma Res       Date:  2018-08-02

6.  PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.

Authors:  Jia Jin; Leiping Wang; Zhonghua Tao; Jian Zhang; Fangfang Lv; Junning Cao; Xichun Hu
Journal:  Mol Med Rep       Date:  2020-03-12       Impact factor: 2.952

7.  Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.

Authors:  Ching-Wen Chou; Yu-Min Huang; Yu-Jia Chang; Chien-Yu Huang; Chin-Sheng Hung
Journal:  Int J Med Sci       Date:  2021-04-26       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.